James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

5 Ambitious Plans From AMZN: Which Will Work?

Amazon has several irons in the fire, though not all of them are reasons to own AMZN stock. But some plans could be very good reasons to be an investor.

Facebook Users Are Getting Older … and That’s a Good Thing

Owners of FB stock worried about aging Facebook users don't need to pull the plug on their position just yet. The numbers explain why.

Abercrombie & Fitch Is Stuck in the 90s

Aeropostale, American Eagle, and Abercrombie & Fitch have managed to work their way into irrelevancy.

3D Printing Stocks: 2 You Want, 3 You Don’t

3D printer makers have had a tough go of things so far this year, but not all 3D printing stocks deserve to be benched.

For JCP Stock Holders, Proposed Poison Pill Isn’t Worth It

The JCPenney Board of Directors makes a great case for its proposed poison pill, but there's a huge downside to it for JCP stock owners.